Russell Investments Group Ltd. Increases Stock Position in InfuSystem Holdings, Inc. $INFU

Key Points

• Russell Investments Group Ltd. increased its stake in InfuSystem Holdings by 13.1% in Q1, now owning 2.08% of the company, worth approximately $2.36 million.
• Hedge funds and institutional investors collectively own 71.13% of InfuSystem, with several funds, including Nuveen Asset Management and Deutsche Bank, significantly increasing their positions in the last quarter.
• Analyst ratings show a mixed outlook on InfuSystem, with Wall Street Zen downgrading the stock to "buy," while B. Riley upgraded it to "strong-buy," and the consensus price target is $12.50.

Russell Investments Group Ltd. boosted its holdings in shares of InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) by 13.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 437,891 shares of the company's stock after buying an additional 50,877 shares during the period. Russell Investments Group Ltd. owned approximately 2.08% of InfuSystem worth $2,356,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of INFU. BNP Paribas Financial Markets raised its holdings in shares of InfuSystem by 67.9% in the fourth quarter. BNP Paribas Financial Markets now owns 6,844 shares of the company's stock valued at $58,000 after purchasing an additional 2,768 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of InfuSystem by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,286 shares of the company's stock valued at $78,000 after purchasing an additional 3,165 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of InfuSystem in the fourth quarter valued at about $98,000. MetLife Investment Management LLC purchased a new stake in shares of InfuSystem in the fourth quarter valued at about $110,000. Finally, Corton Capital Inc. purchased a new stake in shares of InfuSystem in the fourth quarter valued at about $130,000. Institutional investors and hedge funds own 71.13% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on INFU shares. Roth Capital started coverage on shares of InfuSystem in a report on Tuesday, July 22nd. They set a "buy" rating and a $12.00 price objective for the company. B. Riley upgraded shares of InfuSystem to a "strong-buy" rating in a report on Thursday, May 8th. Finally, Wall Street Zen downgraded shares of InfuSystem from a "strong-buy" rating to a "buy" rating in a report on Wednesday, May 14th. Three investment analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, InfuSystem has a consensus rating of "Strong Buy" and an average price target of $12.50.

InfuSystem Price Performance

Shares of INFU stock traded up $0.39 during trading hours on Thursday, reaching $10.73. The stock had a trading volume of 714,870 shares, compared to its average volume of 175,516. The stock's fifty day simple moving average is $7.11 and its 200 day simple moving average is $6.33. The firm has a market capitalization of $219.17 million, a PE ratio of 178.86 and a beta of 1.81. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 12 month low of $4.61 and a 12 month high of $10.90.

Insiders Place Their Bets

In related news, Director Scott Shuda sold 5,752 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $9.67, for a total value of $55,621.84. Following the sale, the director directly owned 94,000 shares of the company's stock, valued at $908,980. This trade represents a 5.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 11.40% of the stock is owned by corporate insiders.

InfuSystem Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.